Controlled release delivery system for nasal application of neurotransmitters

US9186320B2 · kind B2 · utility

Assignee

• MATTERN PHARMA AG · LI

Inventor

• Claudia Mattern · Starnberg, DE

Key dates

• Filing date: Jul 30, 2011
• Grant date: Nov 17, 2015
• Expiry date: Sep 26, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.